NASDAQ: LRMRLarimar Therapeutics Inc Stock
$6.53+0.15 (+2.35%)
Updated Apr 19, 2024
LRMR Price
$6.53
Fair Value Price
$0.48
Market Cap
$416.61M
52 Week Low
$2.18
52 Week High
$13.68
P/E
-7.77x
P/B
5.1x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$36.95M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$33M
Beta
0.65
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
LRMR Overview
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LRMR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LRMR ($6.53) is overvalued by 1,252.05% relative to our estimate of its Fair Value price of $0.48 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LRMR ($6.53) is not significantly undervalued (1,252.05%) relative to our estimate of its Fair Value price of $0.48 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LRMR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LRMR due diligence checks available for Premium users.
Be the first to know about important LRMR news, forecast changes, insider trades & much more!
LRMR News
Valuation
LRMR fair value
Fair Value of LRMR stock based on Discounted Cash Flow (DCF)
Price
$6.53
Fair Value
$0.48
Overvalued by
1,252.05%
LRMR ($6.53) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LRMR ($6.53) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LRMR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LRMR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.77x
Industry
15.81x
Market
40.51x
LRMR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.1x
Industry
5.74x
LRMR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LRMR's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.0M
Profit Margin
0%
LRMR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$95.9M
Liabilities
$14.2M
Debt to equity
0.17
LRMR's short-term assets ($90.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LRMR's short-term assets ($90.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LRMR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LRMR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.3M
Investing
-$2.6M
Financing
$0.0
LRMR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LRMR vs Biotech Stocks
Larimar Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.